Literature DB >> 9669468

Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis.

R L Oliveri1, G Sibilia, P Valentino, C Russo, N Romeo, A Quattrone.   

Abstract

OBJECTIVE: Chronic administration of corticosteroids has been reported to selectively impair explicit memory in systemic diseases without central nervous system involvement. Our aim was to verify that a short course of pulsed intravenous methylprednisolone (IVMP) administered for the treatment of a relapse impairs cognitive functions in relapsing-remitting multiple sclerosis (RRMS) patients and to determine whether this impairment is reversible.
MATERIAL AND METHODS: Neuropsychological evaluations were made before the start of treatment, and 7 and 60 days after the end of treatment in 14 RRMS patients. The neuropsychological battery was also administered to 12 controls matched for age, sex and years of education.
RESULTS: RRMS patients performed worse than the controls at their baseline evaluation for a variety of neuropsychological tasks. IVMP administration induced a selective impairment of explicit memory which completely recovered 60 days after treatment.
CONCLUSIONS: In RRMS patients, IVMP induces a selective and reversible impairment of explicit memory.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669468     DOI: 10.1111/j.1600-0404.1998.tb05967.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

Review 1.  [Effects of high-dose cortisone therapy on cognition].

Authors:  I Uttner; H Tumani
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

Review 2.  Corticosteroids and Cognition: A Meta-Analysis.

Authors:  Catherine E Prado; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2019-05-26       Impact factor: 7.444

3.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

4.  Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis.

Authors:  R S Prakash; E M Snook; J M Lewis; R W Motl; A F Kramer
Journal:  Mult Scler       Date:  2008-08-13       Impact factor: 6.312

Review 5.  Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.

Authors:  Hayrettin Tumani; Ingo Uttner
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

6.  Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.

Authors:  Mazen Abu-Mugheisib; Reiner Benecke; Uwe K Zettl
Journal:  Mult Scler Int       Date:  2011-06-26

7.  The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases.

Authors:  Bun Sheng; Sammy Kin Wing Cheng; Kwok Kwong Lau; Ho Lun Li; Eric Lok Yiu Chan
Journal:  Eur Psychiatry       Date:  2005-05       Impact factor: 5.361

8.  Reduced magnetisation transfer ratio in cognitively impaired patients at the very early stage of multiple sclerosis: a prospective, multicenter, cross-sectional study.

Authors:  J H Faiss; D Dähne; K Baum; R Deppe; F Hoffmann; W Köhler; A Kunkel; A Lux; M Matzke; I K Penner; M Sailer; U K Zettl
Journal:  BMJ Open       Date:  2014-04-10       Impact factor: 2.692

9.  Enduring glucocorticoid-evoked exacerbation of synaptic plasticity disruption in male rats modelling early Alzheimer's disease amyloidosis.

Authors:  Yingjie Qi; Igor Klyubin; Tomas Ondrejcak; Neng-Wei Hu; Michael J Rowan
Journal:  Neuropsychopharmacology       Date:  2021-06-29       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.